CRAd with capsid incorporated mesothelin for higher anti-tumor immunization

van Winkel, Claudia (2018) CRAd with capsid incorporated mesothelin for higher anti-tumor immunization. Research Project, Pharmacy.

Preview	Text Mpharmacy_2018_vanWinkelCAJ.pdf Download (5MB) | Preview
	Text toestemming.pdf Restricted to Registered users only Download (98kB)

Abstract

The adenovirus (Ad) has been widely used as a vaccine because of its unique characteristics as gene transfer vector. The conventional approach for using Ads as vaccine is the insertion of genes encoding the protein of interest into the expression cassette. An alternative approach is the capsid incorporation strategy. This strategy describes the incorporation of antigens into the capsid proteins to achieve higher immunization. To extent the use of the adenovirus, Ads have been modified to work as cancer therapy agents. These conditionally replicative Ad replicate specific in cancer cells, while sparing the normal cells. This project combined the two earlier mentioned strategies to design a vaccine for ovarian cancer. Specifically, the hypothesis testing Ad contains a SPARC promoter and the tumor peptides from mesothelin in capsid protein pIX. The hypothesis of this project is that CRAd with capsid-incorporated mesothelin gives higher anti-tumor immunization then single treatment of CRAd or mesothelin as a transgene. The five Ads for the test of hypothesis are all succesfully produced. It is possible that the mesothelin is not expressed on the capsid surface caused by non-incorporation. Therefore, the expression of mesothelin on the surface should be validated by western blot before immunization can be tested.

Item Type:	Thesis (Research Project)
Supervisor name:	Haisma, H.J.
Degree programme:	Pharmacy
Thesis type:	Research Project
Language:	English
Date Deposited:	28 Jul 2018
Last Modified:	30 Jul 2018 14:13
URI:	https://fse.studenttheses.ub.rug.nl/id/eprint/18108

Actions (login required)

View Item